USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PRECISION GENOME ENGINEERING, INC.
City: SEATTLE
State: WA
Zip+4: 98103-8602
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $472,033.00 2
STTR Phase I $101,156.00 1
STTR Phase II $1,358,027.00 1

Award List:

Engineered nuclease for CCR5 gene editing

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: SEATTLE CHILDREN'S HOSPITAL
Principal Investigator: Andrew M. Scharenberg
Award Amount: $101,156.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): State the application's broad, long-term objectives and specific aims, making reference to the health relatedness of the project (i.e., relevance to the mission of the agency). Describe concisely the research design and methods for achieving these goals.… More

Engineered Nuclease for Glucocorticoid Receptor Gene Editing

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Laurie O. Beitz
Award Amount: $174,053.00
Abstract:
DESCRIPTION (provided by applicant): Genome engineering is an emerging field in which targeted genome modifications are made for biotechnological and therapeutic applications. Site specific rare cutting endonucleases are a crucial tool for genome engin eering, as they are required to create DNA… More

Modular custom nuclease platform for genome engineering therapies

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jordan Jarjour – 206-953-0712
Award Amount: $297,980.00
Abstract:
DESCRIPTION (provided by applicant): Genome engineering is an emerging field in which genomic DNA sequences are modified for biotechnological and therapeutic purposes. Highly specific endonucleases are the key tool that enables genome engineering approaches, as they are required to create… More

Autologous HIV-1 resistant T cells through accelerated CCR5 gene disruption

Award Year / Program / Phase: 2013 / STTR / Phase II
Agency: HHS
Research Institution: SEATTLE CHILDRENS HOSPITAL
Principal Investigator: Christian Burks – 206-225-7477
Award Amount: $1,358,027.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Treating patients infected with Human Immunodeficiency Virus-1 (HIV-1) is a substantial clinical challenge with evolving pharmaceutical drug and dosing options. Treatments should improve the health and quality of life for HIV-infected individuals by reducing… More